1. Home
  2. ASMB vs ANIX Comparison

ASMB vs ANIX Comparison

Compare ASMB & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.08

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.39

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
ANIX
Founded
2005
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
553.6M
135.3M
IPO Year
2010
1987

Fundamental Metrics

Financial Performance
Metric
ASMB
ANIX
Price
$36.08
$3.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$43.40
$9.00
AVG Volume (30 Days)
115.0K
443.3K
Earning Date
11-10-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,191,000.00
N/A
Revenue This Year
$42.01
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
31.30
N/A
52 Week Low
$7.75
$2.07
52 Week High
$39.71
$5.46

Technical Indicators

Market Signals
Indicator
ASMB
ANIX
Relative Strength Index (RSI) 57.52 38.17
Support Level $32.25 $3.18
Resistance Level $36.92 $3.64
Average True Range (ATR) 1.85 0.43
MACD -0.28 -0.17
Stochastic Oscillator 58.31 8.35

Price Performance

Historical Comparison
ASMB
ANIX

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: